INmune Bio Inc INMB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/03/24 EDT
11.57quote price arrow up+0.44 (+3.95%)
Volume
123,322
52 week range
6.50 - 14.74
Loading...
  • Open11.17
  • Day High11.75
  • Day Low11.12
  • Prev Close11.13
  • 52 Week High14.74
  • 52 Week High Date02/14/24
  • 52 Week Low6.50
  • 52 Week Low Date09/20/23

Key Stats

  • Market Cap228.635M
  • Shares Out19.76M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta1.96
  • YTD % Change2.75

KEY STATS

  • Open11.17
  • Day High11.75
  • Day Low11.12
  • Prev Close11.13
  • 52 Week High14.74
  • 52 Week High Date02/14/24
  • 52 Week Low6.50
  • 52 Week Low Date09/20/23
  • Market Cap228.635M
  • Shares Out19.76M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta1.96
  • YTD % Change2.75

RATIOS/PROFITABILITY

  • EPS (TTM)-1.67
  • P/E (TTM)-6.93
  • Fwd P/E (NTM)-4.67
  • EBITDA (TTM)-29.741M
  • ROE (TTM)-61.09%
  • Revenue (TTM)155,000.001
  • Gross Margin (TTM)-
  • Net Margin (TTM)-19,360.00%
  • Debt To Equity (MRQ)26.01%

EVENTS

  • Earnings Date05/06/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On INmune Bio Inc

 

Profile

MORE
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a...
Raymond Tesi M.D.
President, Chief Executive Officer, Director
David Moss
Chief Financial Officer
Address
225 Ne Mizner Blvd, Suite 640
Boca Raton, FL
33432
United States

Top Peers

SYMBOLLASTCHG%CHG
PRLD
Prelude Therapeutics Inc
3.86-0.13-3.26%
OVID
Ovid Therapeutics Inc
3.06-0.01-0.33%
ATNM
Actinium Pharmaceuticals Inc
8.96+0.21+2.40%
GALT
Galectin Therapeutics Inc
3.37UNCHUNCH
DSGN
Design Therapeutics Inc
3.72+0.07+1.92%